Bleb formation induced by acidic mixing buffers improves liquid stability of mRNA-LNPs

This study demonstrates that inducing bleb formation during mRNA-LNP preparation using high ionic strength acidic citrate buffers significantly enhances liquid shelf-life by reducing mRNA degradation and lipid-mRNA adduct formation, offering a universal, chemistry-independent strategy to enable extended refrigerated storage without modifying the mRNA or lipid components.

The Gist

The Big Problem: mRNA is a "Fragile Butterfly"

Imagine mRNA (the genetic instruction manual for vaccines) as a very delicate, beautiful butterfly. To deliver this butterfly into a human cell, scientists wrap it inside a tiny, protective bubble called a Lipid Nanoparticle (LNP).

The problem? These bubbles are like glass houses. If you leave them sitting on a shelf at room temperature, the butterfly inside often gets crushed or eaten by the very walls of the house. This forces vaccines to be kept in ultra-cold freezers (like deep-freeze ice cream), which is expensive and impossible for many parts of the world.

The Discovery: The "Blebbing" Solution

The researchers at AstraZeneca discovered a clever trick to make these bubbles tougher without changing the butterfly or the glass itself. They found that by changing the acidic "soup" used to build the bubble, they could force the bubble to grow a small, protective pouch on its side.

They call this pouch a "bleb."

Think of it like this:

• The Old Way (No Bleb): Imagine the butterfly is stuck right against the glass wall of the bubble. The glass is slightly acidic and rough. Over time, the butterfly rubs against the glass, gets damaged, and dies.
• The New Way (With Bleb): The researchers used a special high-salt, acidic mix (like a strong citrate buffer) to build the bubble. This caused the bubble to puff out a small, water-filled balloon (the bleb) on its side. Now, the butterfly floats safely inside this water balloon, far away from the rough glass walls.

How It Works: The "Safe Room" Analogy

Inside the LNP, there are two main enemies of the mRNA:

1. The Lipid Walls: The building blocks of the bubble can chemically react with the mRNA, breaking it apart (like rust eating through a car).
2. Fragmentation: The mRNA can simply snap into pieces.

When the "bleb" forms, it acts like a safe room or a lifeboat.

• The "rough" parts of the bubble (the ionizable lipids) stay in the main oily core.
• The "precious cargo" (the mRNA) gets pushed into the watery bleb.
• Because they are in different rooms, they can't touch or hurt each other.

The study showed that LNPs with these "blebs" stayed stable for 18.9 days at room temperature, compared to just 2.8 days for the ones without. That is a 7-fold improvement! It's the difference between a sandwich rotting in a day versus lasting a week and a half.

The "Secret Sauce" (The Buffer)

How do you make a bubble grow a bleb? You have to mix the ingredients in a very specific way.

• The researchers tested different "mixing soups" (buffers).
• Acetate soup: Made smooth bubbles with no blebs. The mRNA died quickly.
• Citrate soup (High Salt): Made bubbles with big blebs. The mRNA survived.

It turns out the specific chemical shape of the citrate molecule acts like a key that unlocks the bubble's ability to puff out that protective pouch. Interestingly, this trick worked best with certain types of bubble materials (lipids), but the principle seems to apply broadly.

Why This Matters

This is a game-changer because:

1. No New Chemistry Needed: They didn't have to invent a new drug or change the mRNA sequence. They just changed the recipe for mixing the ingredients.
2. Universal Application: It could work with many different types of mRNA vaccines and therapies.
3. Real-World Impact: If we can keep these vaccines stable at room temperature (or just in a regular fridge), we can send them to remote villages, disaster zones, and countries without expensive freezer trucks. It turns a "fragile butterfly" into a "hardy bird" that can travel anywhere.

In a Nutshell

The scientists figured out that by using a specific salty, acidic mix to build mRNA bubbles, they can force the bubble to grow a protective water-bag (bleb). This keeps the mRNA safe from the bubble's own walls, allowing the vaccine to last much longer on the shelf without needing a freezer. It's a simple, structural fix that could revolutionize how we deliver life-saving medicine to the world.

Technical Summary

1. Problem Statement

Despite the success of mRNA-Lipid Nanoparticle (LNP) vaccines, a major barrier to their widespread adoption as therapeutics is their limited liquid shelf-life. Current formulations often require ultralow temperature cold chains (e.g., -80°C) or have short refrigerated stability, restricting distribution to high-income countries.

• Root Causes: In liquid storage, mRNA-LNPs degrade via two primary mechanisms:
  1. mRNA fragmentation: Breakdown of the mRNA strand.
  2. Lipid-mRNA adduct formation: Covalent bonding between the ionizable lipid and mRNA, often catalyzed by the amine head group of the lipid.
• Limitations of Current Strategies: Existing solutions focus on modifying the mRNA sequence/chemistry or the ionizable lipid structure. However, these approaches can compromise translation efficiency, immunogenicity, or require extensive re-validation. There is a need for a universal, chemistry-agnostic strategy to enhance stability without altering the core drug components.

2. Methodology

The authors investigated the impact of acidic mixing buffers used during the microfluidic formation of LNPs on their subsequent liquid stability.

• LNP Formulation: They synthesized LNPs using the ionizable lipid MC3 (and later other lipids like SM-102, Lipid 365, 370, 29, and L15) with helper lipids (DSPC, Cholesterol, DMG-PEG2kDa) and Firefly Luciferase (FLuc) mRNA.
• Variable Manipulation: The mRNA was diluted in various acidic buffers (pH 3–4) with varying ionic strengths and buffer species (acetate, citrate, citrate-phosphate, gluconate, tartrate, succinate, malate).
  • Low Ionic Strength: 25 mM Acetate.
  • High Ionic Strength: 300 mM Citrate, 300 mM Citrate-Phosphate.
• Storage Conditions: Post-formation, LNPs were dialyzed into a standard neutral storage buffer (20 mM Tris, 10% sucrose, pH 7.4) and stored at 25°C for up to 4–5 weeks.
• Characterization Techniques:
  • In Vitro Activity: Transfection efficiency measured via luciferase luminescence in HeLa cells.
  • mRNA Integrity: Purity, fragmentation, and lipid-mRNA adducts analyzed via Reverse-Phase Ion-Pairing (RP-IP) HPLC.
  • Morphology: Particle size (DLS) and internal structure visualized via Cryo-TEM to detect "bleb" formation (mRNA-filled protrusions attached to the LNP core).

3. Key Contributions

• Discovery of a Universal Stabilization Mechanism: The study identifies that bleb formation induced by high ionic strength acidic buffers (specifically citrate) is the critical factor improving liquid stability, independent of specific lipid or mRNA modifications.
• Decoupling Stability from Chemistry: The authors demonstrate that stability can be enhanced by optimizing the process (mixing buffer) rather than the formulation chemistry (lipid/mRNA structure).
• Mechanistic Insight: They propose a structural model where blebs physically segregate the mRNA from the ionizable lipid, preventing the chemical interactions that lead to degradation.

4. Key Results

• Dramatic Improvement in Shelf-Life:
  • MC3-LNPs prepared with 300 mM Citrate (pH 4) showed a ~7-fold increase in liquid storage half-life at 25°C compared to those prepared with low ionic strength acetate (18.9 days vs. 2.8 days).
  • After 4 weeks at 25°C, Citrate-prepared LNPs retained ~50% of initial activity, whereas Acetate-prepared LNPs lost almost all activity within one week.
• Correlation with Bleb Formation:
  • Cryo-TEM revealed that high ionic strength citrate buffers induced significant bleb formation (up to 83% of particles had blebs), whereas low ionic strength acetate buffers resulted in negligible blebs (<5%).
  • High bleb formation correlated directly with high mRNA purity and retained transfection activity.
• Mechanism of Degradation Prevention:
  • Acetate (Low Bleb): Rapid degradation driven primarily by lipid-mRNA adduct formation (>85% adducts after 1 week).
  • Citrate (High Bleb): Significantly reduced adduct formation and fragmentation. The authors propose that in blebbed LNPs, the mRNA is sequestered in an aqueous "liposomal-like" compartment, while the ionizable lipid resides in a hydrophobic "solid core," minimizing unfavorable interactions.
• Dependence on Lipid and Buffer Species:
  • Lipid Head Group: The stabilization effect varied by lipid type. While citrate buffers improved stability for most lipids, some (e.g., Lipid 365/370 with 3-hydroxymethyl azetidine heads) showed poor stability regardless of the buffer, suggesting lipid chemistry still plays a role.
  • Buffer Specificity: Among 50 mM buffers, Citrate and Malate induced the most blebs and stability. Tartrate induced high bleb formation but resulted in lower stability than citrate, suggesting factors beyond ionic strength (e.g., specific ion interactions or Hofmeister effects) influence the outcome.

5. Significance

• Scalable Solution: This approach offers a simple, cost-effective, and scalable method to extend the shelf-life of mRNA-LNPs without requiring complex chemical synthesis of new lipids or mRNA sequences.
• Cold Chain Reduction: By extending liquid stability at 25°C (or potentially 2–8°C), this strategy could enable the distribution of mRNA therapeutics to regions lacking ultralow temperature infrastructure, crucial for global health equity.
• Universal Applicability: The strategy is broadly applicable across different ionizable lipids and mRNA constructs, making it a versatile tool for the biopharmaceutical industry.
• Fundamental Understanding: The work provides critical insight into the structural dynamics of LNPs, highlighting that particle morphology (blebs) is a key determinant of intraparticle chemical stability.

Conclusion: The paper establishes that inducing bleb formation via high ionic strength acidic citrate buffers during LNP manufacturing is a powerful, universal strategy to mitigate mRNA degradation, significantly extending the liquid shelf-life of mRNA-LNP therapeutics.